ClinicalTrials.gg
TerminatedNCT01085331Updated Oct 19, 2016Results posted

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

A Phase 1/2 interventional study of Pimasertib and Placebo in Metastatic Colorectal Cancer, sponsored by EMD Serono. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-19.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Conduct the randomized Phase 2 part not recommended due to the achieved MTD for pimasertib (45mg/day) in combination with FOLFIRI

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany — 1 open to participants now, 2 under way, 1 of them phase 3. Colorectal Neoplasms · Merck KGaA, Darmstadt, Germany.

Enrollment
13th of 15
16 · median 220
Started
2010
with 1 other
Phase 1/2
3 of 21
none open now
Registered
9th of 21
by date

Among the 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2010, is one of 3 in phase 1/2, and was the 9th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Colorectal Neoplasms by Merck KGaA, Darmstadt, Germany, or all of them as a file.
02

Study summary

The research trial is testing the experimental treatment pimasertib (MSC1936369B) in combination with FOLFIRI, as second-line treatment in metastatic K Ras mutated colorectal cancer subjects. The study will be run in two parts:

Part 1, or Safety Run-in Part: Will determine the maximum tolerated dose and the recommended Phase 2 dose (RP2D) of pimasertib combined with FOLFIRI as second-line treatment in subjects with metastatic K Ras mutated colorectal cancer.

Part 2 or Phase 2 Randomised Part: Will assess the anti-tumor activity of pimasertib combined with FOLFIRI compared to FOLFIRI with placebo as second-line treatment in metastatic K Ras mutated colorectal cancer subjects.

Phase I which Is an open label dose escalation "3+3" cohort, non-randomized, safety Phase II which is a double blind randomized safety/efficacy

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Mek Inhibitor
  • Metastatic Colorectal Cancer
  • K-Ras Mutation
  • Phase II
  • Second line K-Ras mutated metastatic colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Safety Run-in and Part 2 or Phase 2 Randomised Part

  • confirmed K-Ras mutated colon/rectum cancer
  • Subject's disease must have progressed during or after a treatment for disease with oxaliplatin and fluoropyrimidines based chemotherapy with or without bevacizumab
  • Evidence of metastatic at trial entry as per . Complete tumor assessment performed within 14 days prior to first trial drug administration
  • Male/female subjects aged greater than or equal to (>=) 18 years
  • Subject has read and understood the form
  • Women of must have a negative blood pregnancy test at the screening visit. Subjects and their partners must be willing to avoid pregnancy during the trial

Exclusion criteria

Exclusion Criteria:

For Safety Run-in and Part 2 or Phase 2 Randomised Part

  • Bone marrow impairment
  • Renal impairment
  • Liver function and liver cell integrity abnormality
  • History of central nervous system (CNS)
  • History of difficulty of swallowing, malabsorption or other chronic gastrointestinal disease
  • Performance Status (ECOG PS) greater than (>)1
  • Known (HIV) positivity, active , or active
  • Has received extensive prior radiotherapy on more than 30 percent (%) of bone marrow reserves, or prior bone marrow/stem cell transplantation
  • Has received chemotherapy, any drug, or having participated in another clinical trial within the past 4 weeks prior to trial first drug administration
  • Has a history of any other significant medical disease
  • Past or current history (within the last 2 years prior to inclusion) of except for the indication under this study
  • Has significant cardiac conduction abnormalities and/or pacemaker
  • Is a pregnant or nursing female
  • Has retinal degenerative disease, history of uveitis, or history of retinal vein occlusion
  • Other significant disease that in the Investigator's opinion would exclude the subject from the trial
  • Known to the trial treatment(s) or diluents (when applicable), including placebo or other comparator drug(s)
  • Legal incapacity or limited legal capacity
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI

    Drug: Pimasertib · Drug: FOLFIRI

  • Experimental
    Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI

    Planned, not performed

    Drug: Pimasertib · Drug: FOLFIRI

  • Experimental
    Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI

    Planned, not performed

    Drug: Placebo · Drug: FOLFIRI

Interventions

  • Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.

    Also known as: MSC1936369B

  • DrugPlacebo

    Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.

  • DrugFOLFIRI

    Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.

06

What researchers measure

Primary outcomes

  1. Part 1 or Safety Run-in Part: Maximum Tolerated Dose (MTD)

    MTD was defined as the dose level, at which the treatment-related dose limiting toxicity (DLT) occurred in \>1 of 3 subjects or in \>1 of 6 subjects. DLT was defined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Any Grade \>=3 non-hematological toxicity except for Grade 4 asymptomatic increases in liver function tests (LFTs) reversible within 7 days in subjects with liver involvement, Grade 3 asymptomatic increases in LFTs reversible within 7 days in subjects without liver involvement, Grade 3 vomiting controlled with adequate and optimal therapy and prophylaxis, and Grade 3 diarrhea controlled with adequate and optimal anti-diarrhea therapy; any Grade 4 neutropenia lasing \>5 days/ febrile neutropenia lasting \>1 day; any Grade 4 thrombocytopenia/Grade 3 with bleeding; any treatment delay \>2 weeks due to trial treatment-related adverse effects at any dose level and judged to be possibly or probably related to the trial treatment.

    Time frame: Baseline up to Day 28 (Part 1)

  2. Part 2 or Phase 2 Randomised Part: Progression Free Survival (PFS)

    PFS was defined as time (in months) from the date of randomization to the first documentation of disease progression as reported and documented by the Investigator (i.e. radiological progression per RECIST v1.0) or death for any cause.

    Time frame: From randomization up to first documented disease progression maximum up to 2 years

Secondary outcomes

  1. Part 1 or Safety Run-in Part: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

    An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the first dose of study drug administration up to 28 days after the last dose of study drug administration

  2. Part 1 or Safety Run-in Part: Maximum Observed Plasma Concentration (Cmax) of Pimasertib, Irinotecan and SN-38

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38

  3. Part 1 or Safety Run-in Part: Time to Reach Maximum Observed Concentration (Tmax) of Pimasertib, Irinotecan and SN-38

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38

  4. Part 1 or Safety Run-in Part: Area Under the Concentration-time Curve From Time Zero to the Time of Last Observation (AUC0-t) of Pimasertib, Irinotecan and SN-38

    Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration is at or above the lower limit of quantification.

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38

  5. Part 1 or Safety Run-in Part: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib, Irinotecan and SN-38

    The AUC(0-inf) of pimasertib and irinotecan was estimated by determining the total area under the concentration time curve extrapolated to infinity.

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38

  6. Part 1 or Safety Run-in Part: Apparent Terminal Half Life (t1/2) of Pimasertib, Irinotecan and SN-38

    The t1/2 was defined as the time required for the plasma concentration of pimasertib and irinotecan to decrease 50% in the final stage of elimination.

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38

  7. Part 1 or Safety Run-in Part: Apparent Oral Clearance (CL/f) of Pimasertib, (CL) Irinotecan and SN-38

    Clearance of a drug was a measure of the rate at which drug was metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38

  8. Part 1 or Safety Run-in Part: Apparent Oral Volume of Distribution (Vz f) Pimasertib, (Vz) of Irinotecan and SN-38

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38

  9. Part 1 or Safety Run-in Part: Ratio of Cmax for Pimasertib (Day 1/Day 8), Irinotecan and SN-38 (Day 1/Day 15)

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38

  10. Part 1 or Safety Run-in Part: Ratio of AUC0-inf of Pimasertib (Day 1/Day 8), Irinotecan and SN-38 (Day 1/Day 15)

    The AUC(0-inf) was estimated by determining the total area under the concentration time curve extrapolated to infinity.

    Time frame: Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan

  11. Part 1 or Safety Run-in Part: Number of Subjects With Best Overall Response (BOR)

    BOR was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST V1.0) as following: Complete response (CR) was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) was defined as at least a 30 percent (%) decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks (28 days). Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) being demonstrated during the first 4 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.

    Time frame: Up to 2 years

  12. Part 1 or Safety Run-in Part: Circulating Biomarkers in Serum

    Time frame: Predose, Day 1, 2 and 16 of cycle 1 followed by Day 1 pre-dose of every second cycle up to 2 years

  13. Part 2 or Phase 2 Randomized Part: Circulating Biomarkers

    Time frame: Predose, Day 1, 2 and 16 of cycle 1 followed by Day 1 pre-dose of every second cycle up to 2 years

  14. Part 2 or Phase 2 Randomized Part: Best Overall Response

    BOR was defined based on Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST V1.0) as following: Complete response (CR) was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) was defined as at least a 30 percent (%) decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks (28 days). Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) being demonstrated during the first 4 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.

    Time frame: Up to 2 years

  15. Part 2 or Phase 2 Randomized Part: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

    An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAES between first dose of study drug administration and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the first dose of study drug administration up to 28 days after the last dose of study drug administration

07

Results

Posted Oct 19, 2016
Limitations and caveats
During the trial, the decision was made not to perform the Phase 2 part of the study due to the achieved MTD for pimasertib (45mg/day) in combination with FOLFIRI, so that no further dose escalation was possible as per the protocol.

Participant flow

First/last subject (informed consent): March 2010/September 2011. Last subject completed:May 2012.

Participant flow — Overall Study
MilestonePart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Started106
Completed106
Not completed00

Outcome measures

PrimaryPart 1 or Safety Run-in Part: Maximum Tolerated Dose (MTD)

MTD was defined as the dose level, at which the treatment-related dose limiting toxicity (DLT) occurred in \>1 of 3 subjects or in \>1 of 6 subjects. DLT was defined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Any Grade \>=3 non-hematological toxicity except for Grade 4 asymptomatic increases in liver function tests (LFTs) reversible within 7 days in subjects with liver involvement, Grade 3 asymptomatic increases in LFTs reversible within 7 days in subjects without liver involvement, Grade 3 vomiting controlled with adequate and optimal therapy and prophylaxis, and Grade 3 diarrhea controlled with adequate and optimal anti-diarrhea therapy; any Grade 4 neutropenia lasing \>5 days/ febrile neutropenia lasting \>1 day; any Grade 4 thrombocytopenia/Grade 3 with bleeding; any treatment delay \>2 weeks due to trial treatment-related adverse effects at any dose level and judged to be possibly or probably related to the trial treatment.

Time frame:
Baseline up to Day 28 (Part 1)
Reported as:
Number · mg
Part 1 or Safety Run-in Part: Maximum Tolerated Dose (MTD)
mgPimasertib+FOLFIRI (Overall)
Part 1 or Safety Run-in Part: Maximum Tolerated Dose (MTD)45
PrimaryPart 2 or Phase 2 Randomised Part: Progression Free Survival (PFS)

PFS was defined as time (in months) from the date of randomization to the first documentation of disease progression as reported and documented by the Investigator (i.e. radiological progression per RECIST v1.0) or death for any cause.

Time frame:
From randomization up to first documented disease progression maximum up to 2 years

No measurements were reported for this outcome.

SecondaryPart 1 or Safety Run-in Part: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From the first dose of study drug administration up to 28 days after the last dose of study drug administration
Reported as:
Number · Subjects
Part 1 or Safety Run-in Part: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
SubjectsPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
TEAE106
Serious TEAE44
TEAEs leading to discontinuation64
TEAEs leading to death00
SecondaryPart 1 or Safety Run-in Part: Maximum Observed Plasma Concentration (Cmax) of Pimasertib, Irinotecan and SN-38
Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Reported as:
Median · nanogram per milliliter (ng/mL)
Part 1 or Safety Run-in Part: Maximum Observed Plasma Concentration (Cmax) of Pimasertib, Irinotecan and SN-38
nanogram per milliliter (ng/mL)Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib: Day 1 (n=9, 6)145 (82.3 to 418)386 (163 to 516)
Pimasertib: Day 8 (n=9, 6)196 (71.6 to 660)332 (214 to 638)
Irinotecan: Day 1 (n=10, 6)2070 (1590 to 3060)1850 (1230 to 2110)
Irinotecan: Day 15 (n=8, 6)2120 (1760 to 2840)1540 (1330 to 2420)
SN-38: Day 1 (n=10, 6)20.4 (11.4 to 37.6)21.9 (15.8 to 46.3)
SN-38: Day 15 (n=8, 6)15.1 (9.28 to 37.5)27 (9.31 to 51.2)
SecondaryPart 1 or Safety Run-in Part: Time to Reach Maximum Observed Concentration (Tmax) of Pimasertib, Irinotecan and SN-38
Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Reported as:
Median · hour
Part 1 or Safety Run-in Part: Time to Reach Maximum Observed Concentration (Tmax) of Pimasertib, Irinotecan and SN-38
hourPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib: Day 1 (n=9, 6)2 (1.00 to 6.00)0.79 (0.50 to 4.00)
Pimasertib: Day 8 (n=9, 6)1.5 (0.53 to 2.00)1.25 (0.50 to 2.50)
Irinotecan: Day 1 (n=10, 6)1.5 (1.25 to 2.50)1.5 (1.50 to 2.50)
Irinotecan: Day 15 (n=8, 6)1.54 (1.50 to 2.50)1.56 (1.50 to 4.00)
SN-38: Day 1 (n=10, 6)1.5 (1.50 to 2.25)1.5 (1.50 to 4.00)
SN-38: Day 15 (n=8, 6)1.6 (1.50 to 2.50)2.5 (1.50 to 4.33)
SecondaryPart 1 or Safety Run-in Part: Area Under the Concentration-time Curve From Time Zero to the Time of Last Observation (AUC0-t) of Pimasertib, Irinotecan and SN-38

Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration is at or above the lower limit of quantification.

Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Reported as:
Median · (nanogram/milliliter)*hour([ng/mL]*hour)
Part 1 or Safety Run-in Part: Area Under the Concentration-time Curve From Time Zero to the Time of Last Observation (AUC0-t) of Pimasertib, Irinotecan and SN-38
(nanogram/milliliter)*hour([ng/mL]*hour)Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib: Day 1 (n=9, 5)1120 (194 to 1860)1390 (666 to 2190)
Pimasertib: Day 8 (n=8, 5)1270 (190 to 2030)1260 (858 to 2060)
Irinotecan: Day 1 (n=10, 6)10500 (7130 to 18500)10200 (6220 to 11300)
Irinotecan: Day 15 (n=8, 6)12700 (7040 to 17900)11400 (7050 to 13400)
SN-38: Day 1 (n=10, 6)10500 (7130 to 18500)10200 (6220 to 11300)
SN-38: Day 15 (n=8, 6)12700 (7040 to 17900)11400 (7050 to 13400)
SecondaryPart 1 or Safety Run-in Part: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib, Irinotecan and SN-38

The AUC(0-inf) of pimasertib and irinotecan was estimated by determining the total area under the concentration time curve extrapolated to infinity.

Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Reported as:
Median · ng/mL*hour
Part 1 or Safety Run-in Part: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib, Irinotecan and SN-38
ng/mL*hourPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib: Day 1 (n=7, 5)1160 (226 to 1950)1430 (673 to 2310)
Pimasertib: Day 8 (n=8, 5)1340 (244 to 2140)1340 (869 to 2170)
Irinotecan: Day 1 (n=9, 6)10600 (7650 to 20600)11200 (6560 to 12500)
Irinotecan: Day 15 (n=8, 6)13600 (7330 to 20400)12300 (7520 to 14500)
SN-38: Day 1 (n=9, 6)10600 (7650 to 20600)11200 (6560 to 12500)
SN-38: Day 15 (n=8, 6)13600 (7330 to 20400)12300 (7520 to 14500)
SecondaryPart 1 or Safety Run-in Part: Apparent Terminal Half Life (t1/2) of Pimasertib, Irinotecan and SN-38

The t1/2 was defined as the time required for the plasma concentration of pimasertib and irinotecan to decrease 50% in the final stage of elimination.

Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Reported as:
Median · hour
Part 1 or Safety Run-in Part: Apparent Terminal Half Life (t1/2) of Pimasertib, Irinotecan and SN-38
hourPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib: Day 1 (n=7, 5)5.31 (2.37 to 5.97)5.56 (3.53 to 6.56)
Pimasertib: Day 8 (n=8, 5)5.12 (3.88 to 7.27)5.08 (4.27 to 6.25)
Irinotecan: Day 1 (n=9, 6)6.43 (5.32 to 7.63)6.83 (5.46 to 7.85)
Irinotecan: Day 15 (n=8, 6)6.21 (5.54 to 8.77)6.45 (5.59 to 7.21)
SN-38: Day 1 (n=9, 6)6.43 (5.32 to 7.63)6.83 (5.46 to 7.85)
SN-38: Day 15 (n=8, 6)6.21 (5.54 to 8.77)6.45 (5.59 to 7.21)
SecondaryPart 1 or Safety Run-in Part: Apparent Oral Clearance (CL/f) of Pimasertib, (CL) Irinotecan and SN-38

Clearance of a drug was a measure of the rate at which drug was metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Reported as:
Median · Liter per hour
Part 1 or Safety Run-in Part: Apparent Oral Clearance (CL/f) of Pimasertib, (CL) Irinotecan and SN-38
Liter per hourPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib: Day 1 (n=7, 5)38.7 (23.1 to 199)42.1 (25.9 to 89.1)
Pimasertib: Day 8 (n=8, 5)34.2 (21.0 to 184)44.6 (27.6 to 69.1)
Irinotecan: Day 1 (n=9, 6)29.4 (16.4 to 47.0)29.7 (25.9 to 42.7)
Irinotecan: Day 15 (n=8, 6)23.5 (15.6 to 46.8)26.2 (20.9 to 37.3)
SN-38: Day 1 (n=9, 6)29.4 (16.4 to 47.0)29.7 (25.9 to 42.7)
SN-38: Day 15 (n=8, 6)23.5 (15.6 to 46.8)26.2 (20.9 to 37.3)
SecondaryPart 1 or Safety Run-in Part: Apparent Oral Volume of Distribution (Vz f) Pimasertib, (Vz) of Irinotecan and SN-38

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.

Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Reported as:
Median · Liter
Part 1 or Safety Run-in Part: Apparent Oral Volume of Distribution (Vz f) Pimasertib, (Vz) of Irinotecan and SN-38
LiterPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib: Day 1 (n=7, 5)276 (197 to 680)348 (210 to 570)
Pimasertib: Day 8 (n=8, 5)265 (189 to 1030)395 (246 to 425)
Irinotecan: Day 1 (n=9, 6)297 (147 to 455)313 (241 to 395)
Irinotecan: Day 15 (n=8, 6)212 (143 to 382)253 (182 to 336)
SN-38: Day 1 (n=9, 6)297 (147 to 455)313 (241 to 395)
SN-38: Day 15 (n=8, 6)212 (143 to 382)253 (182 to 336)
SecondaryPart 1 or Safety Run-in Part: Ratio of Cmax for Pimasertib (Day 1/Day 8), Irinotecan and SN-38 (Day 1/Day 15)
Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan and SN-38
Reported as:
Median · Ratio of Cmax
Part 1 or Safety Run-in Part: Ratio of Cmax for Pimasertib (Day 1/Day 8), Irinotecan and SN-38 (Day 1/Day 15)
Ratio of CmaxPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib (n=8, 5)0.837 (0.345 to 1.18)0.751 (0.359 to 2.22)
Irinotecan (n=8, 6)0.973 (0.623 to 1.13)1.09 (0.774 to 1.40)
SN-38 (n=8, 6)0.973 (0.623 to 1.13)1.09 (0.774 to 1.40)
SecondaryPart 1 or Safety Run-in Part: Ratio of AUC0-inf of Pimasertib (Day 1/Day 8), Irinotecan and SN-38 (Day 1/Day 15)

The AUC(0-inf) was estimated by determining the total area under the concentration time curve extrapolated to infinity.

Time frame:
Day 1 and Day 8 for pimasertib; Day 1 and Day 15 for Irinotecan
Reported as:
Median · Ratio
Part 1 or Safety Run-in Part: Ratio of AUC0-inf of Pimasertib (Day 1/Day 8), Irinotecan and SN-38 (Day 1/Day 15)
RatioPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Pimasertib (n=7, 4)0.917 (0.738 to 1.22)0.825 (0.759 to 1.21)
Irinotecan (n=8, 6)0.911 (0.577 to 1.08)0.844 (0.697 to 1.17)
SN-38 (n=8, 6)0.911 (0.577 to 1.08)0.844 (0.697 to 1.17)
SecondaryPart 1 or Safety Run-in Part: Number of Subjects With Best Overall Response (BOR)

BOR was defined based on Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST V1.0) as following: Complete response (CR) was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) was defined as at least a 30 percent (%) decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks (28 days). Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) being demonstrated during the first 4 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.

Time frame:
Up to 2 years
Reported as:
Number · Subjects
Part 1 or Safety Run-in Part: Number of Subjects With Best Overall Response (BOR)
SubjectsPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
CR00
PR11
SD63
PD12
Not evaluable10
SecondaryPart 1 or Safety Run-in Part: Circulating Biomarkers in Serum
Time frame:
Predose, Day 1, 2 and 16 of cycle 1 followed by Day 1 pre-dose of every second cycle up to 2 years

No measurements were reported for this outcome.

SecondaryPart 2 or Phase 2 Randomized Part: Circulating Biomarkers
Time frame:
Predose, Day 1, 2 and 16 of cycle 1 followed by Day 1 pre-dose of every second cycle up to 2 years

No measurements were reported for this outcome.

SecondaryPart 2 or Phase 2 Randomized Part: Best Overall Response

BOR was defined based on Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST V1.0) as following: Complete response (CR) was defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) was defined as at least a 30 percent (%) decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks (28 days). Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD) being demonstrated during the first 4 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryPart 2 or Phase 2 Randomized Part: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death

An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAES between first dose of study drug administration and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From the first dose of study drug administration up to 28 days after the last dose of study drug administration

No measurements were reported for this outcome.

Adverse events

Collected over From the first dose of study drug administration up to 28 days after the last dose of study drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRI—4/10 (40%)10/10 (100%)
Part 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI—4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
Mucosal inflammationGeneral disorders0/102/6
EnteritisGastrointestinal disorders0/101/6
General physical health deteriorationGeneral disorders0/101/6
PyrexiaGeneral disorders0/101/6
Memory impairmentNervous system disorders0/101/6
DiarrhoeaGastrointestinal disorders1/100/6
Intestinal obstructionGastrointestinal disorders1/100/6
VomitingGastrointestinal disorders1/100/6
AstheniaGeneral disorders1/100/6
CardiomyopathyCardiac disorders1/100/6
Most frequent other events
Showing 10 of 75
Most frequent other events
EventPart 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRI
DiarrhoeaGastrointestinal disorders8/105/6
StomatitisGastrointestinal disorders2/105/6
AstheniaGeneral disorders6/104/6
VomitingGastrointestinal disorders4/104/6
RashSkin and subcutaneous tissue disorders4/104/6
NeutropeniaBlood and lymphatic system disorders2/104/6
NauseaGastrointestinal disorders5/103/6
Abdominal painGastrointestinal disorders3/103/6
Decreased appetiteMetabolism and nutrition disorders2/103/6
DyspepsiaGastrointestinal disorders0/102/6

Baseline characteristics

The safety analysis set included all subjects who received at least one (non-zero) administration of the trial medication (any of the 3 FOLFIRI drugs and pimasertib).

Age, Continuous
Age, Continuous(Years)Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRITotal
Mean62.3 ± 12.060.4 ± 17.261.6 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 or Safety Run-in Part: Pimasertib 45 mg +FOLFIRIPart 1 or Safety Run-in Part: Pimasertib 60 mg +FOLFIRITotal
Female527
Male549
08

Study locations

3 sites
  • Research Site
    Leuven, Belgium
  • Research Site
    Napoli, Italy
  • Research Site
    Barcelona, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2010
First posted
Mar 11, 2010
Start
Mar 2010
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Oct 19, 2016
Last update
Oct 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01085331
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Mar 11, 2010
Start date
Mar 2010
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Oct 19, 2016
Last update
Oct 19, 2016

Study contacts

Medical Responsible
study director · Merck Serono S.A., Geneva

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimasertib

Start the discussion